ImmueMed
Contact Us
KO
Company
Company Introduction
CEO Greeting
Organizational Status
Mission & Business Strategy
Direction
R & D
Antiviral Agent
Research Projects
Pipeline
Company News
Publicity
Investment Information
Notice
Financial Information
Investment Inquiry
Company
Company Introduction
CEO Greeting
Organizational Status
Mission & Business Strategy
Direction
R & D
Antiviral Agent
Research Projects
Pipeline
Company News
Publicity
Investment Information
Notice
Financial Information
Investment Inquiry
Overall Menu
Company
Company
Introduction
CEO Greeting
Organizational Status
Mission & Business Strategy
Direction
R & D
Antiviral Agent
Research Projects
Pipeline
Company News
Publicity
Investment Information
Investment
Information
Notice
Financial Information
Investment Inquiry
Press Release | ImmuneMed
Press Release
Home
Company News
Company
R & D
Company News
Investment Information
Publicity
Publicity
Press Release
Video Clip
COVID-19 Phase 2 Clinical Study Approval (Italy), December 18th, 2020
Writer
|
ImmuneMed
Views
|
6034
Date
|
2020-12-21
Prev 및 Next
Prev
[Press Release] ImmuneMed's hzVSF-v13, COVID-19 clinical trials accelerate
development of the treatment
2021-01-08
Next
Obtaining Approval Letter of Investigational New Drug (IND) for COVID-19 Phase 2
Study in Republic of Korea on 7th December, 2020
2020-12-07
.jpg "이탈리아%20임상2상%20승인서(1).jpg")
%202(1).jpg "승인서(이탈리아)%202(1).jpg")